FWM
TOVX icon

Focused Wealth Management’s Theriva Biologics TOVX Stock Holding History

Focused Wealth Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2
Closed – – 1173
2022
Q3 		$0 Hold
2
– – ﹤0.01% 1061
2022
Q2 		$0 Hold
2
– – ﹤0.01% 1079
2022
Q1 		$0 Hold
2
– – ﹤0.01% 1108
2021
Q4 		$0 Hold
2
– – ﹤0.01% 1098
2021
Q3 		$0 Hold
2
– – ﹤0.01% 1105
2021
Q2 		$0 Hold
2
– – ﹤0.01% 1035
2021
Q1 		$0 Buy
+2
New +$395 ﹤0.01% 1006

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Focused Wealth Management's TOVX Position: Q4 2022 in Review

Focused Wealth Management sold out of Theriva Biologics (TOVX) in Q4 2022, closing a stake of 2 shares.

Focused Wealth Management first reported a position in TOVX in Q1 2021 and held it in 7 quarters. The position peaked at $0 in Q3 2022. 20 funds tracked by Wall St. Rank hold TOVX as of Q4 2022.

  • Focused Wealth Management reported no remaining Theriva Biologics position as of Q4 2022 after selling out during the quarter.
  • Focused Wealth Management sold 2 Theriva Biologics shares in Q4 2022.
  • Focused Wealth Management first reported a position in Theriva Biologics in Q1 2021 and held it in 7 quarters.
  • Focused Wealth Management's Theriva Biologics position peaked at $0 in Q3 2022.
  • 20 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2022.

Based on Focused Wealth Management's 13F filing for Q4 2022, filed 13 Jan 2023.